Archive ready

2026年3月期 第2四半期決算短信〔日本基準〕(連結)

https://www.cawachi.co.jp/wp/wp-content/uploads/ir-tan20251029.pdf
May 13, 2026 at 12:30 AM JSTThe archive page, viewer, and downloads use this saved version.
May 13, 2026 at 12:30 AM JST·www.cawachi.co.jp

The evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.

Saved PDF

2026年3月期 第2四半期決算短信〔日本基準〕(連結)

StartedMay 13, 2026 at 12:30 AM JST
File size0.23 MB
SHA-25682c33f3445277e2937542c4781fbeba8993ab1e6e065b1cc987d30fcb2dd43b1
About this pageAI generated

This document is the financial results report for the second quarter (interim period) of the fiscal year ending March 2026 for Kawachi Pharmaceutical Co., Ltd., published on October 29, 2025. The report indicates that sales amounted to 145.357 billion yen, a 1.4% decrease compared to the same period last year. Operating profit decreased by 21.9% to 3.209 billion yen, while ordinary profit fell by 16.2% to 3.806 billion yen. Net profit attributable to shareholders was 2.457 billion yen, down 9.5%. Despite a gradual economic recovery, the company faces intensified competition and rising prices. Kawachi Pharmaceutical has expanded its product offerings in health foods and adjusted prices, operating a total of 385 stores.